Royal Bank Of Canada reaffirmed their buy rating on shares of Johnson & Johnson (NYSE:JNJ) in a research note issued to investors on Thursday morning. The brokerage currently has a $128.00 target price on the stock.

Several other research analysts have also weighed in on the company. Cowen and Company reaffirmed an outperform rating and set a $143.00 price target on shares of Johnson & Johnson in a research report on Tuesday, June 13th. BMO Capital Markets reaffirmed a buy rating and set a $132.00 price target on shares of Johnson & Johnson in a research report on Friday, June 2nd. Vetr raised Johnson & Johnson from a hold rating to a buy rating and set a $132.33 price target on the stock in a research report on Monday, May 29th. BTIG Research reaffirmed a hold rating on shares of Johnson & Johnson in a research report on Sunday, May 21st. Finally, Morgan Stanley reaffirmed an equal weight rating and set a $135.00 price target (up previously from $130.00) on shares of Johnson & Johnson in a research report on Friday, May 19th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Johnson & Johnson has an average rating of Buy and an average target price of $131.17.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE JNJ) opened at 134.36 on Thursday. The company has a market cap of $361.94 billion, a PE ratio of 22.59 and a beta of 0.81. The firm’s 50-day moving average price is $127.78 and its 200-day moving average price is $121.47. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $134.68.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 18th. The company reported $1.83 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.77 by $0.06. The firm had revenue of $17.77 billion for the quarter, compared to analyst estimates of $18.02 billion. Johnson & Johnson had a return on equity of 26.50% and a net margin of 22.87%. The business’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.68 EPS. Equities analysts predict that Johnson & Johnson will post $7.11 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson’s (JNJ) Buy Rating Reiterated at Royal Bank Of Canada” was first reported by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.dailypolitical.com/2017/06/20/johnson-johnsons-jnj-buy-rating-reiterated-at-royal-bank-of-canada.html.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 13th. Investors of record on Tuesday, May 30th were given a dividend of $0.84 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 2.51%. The ex-dividend date was Thursday, May 25th. Johnson & Johnson’s dividend payout ratio is currently 56.47%.

Several hedge funds have recently made changes to their positions in the company. Lau Associates LLC increased its stake in shares of Johnson & Johnson by 12.8% in the first quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock valued at $5,839,000 after buying an additional 5,335 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in shares of Johnson & Johnson by 396.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 110,823 shares of the company’s stock valued at $12,768,000 after buying an additional 88,510 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its stake in shares of Johnson & Johnson by 7.3% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock valued at $1,627,000 after buying an additional 957 shares in the last quarter. Clark Capital Management Group Inc. increased its stake in shares of Johnson & Johnson by 3.3% in the fourth quarter. Clark Capital Management Group Inc. now owns 190,053 shares of the company’s stock valued at $21,896,000 after buying an additional 6,135 shares in the last quarter. Finally, Coho Partners Ltd. increased its stake in shares of Johnson & Johnson by 0.6% in the fourth quarter. Coho Partners Ltd. now owns 529,138 shares of the company’s stock valued at $60,962,000 after buying an additional 3,201 shares in the last quarter. Institutional investors and hedge funds own 66.76% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.